文献速递创伤与烧伤重症综合管理与镇静镇痛

大剂量静脉维生素C对严重烧伤患者死亡率和器官功能障碍的影响:VICTORY随机临床试验

High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury: The VICTORY Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论在严重烧伤成人中,大剂量静脉维生素C(50 mg/kg每6小时共96小时)未减少28天死亡率和持续器官功能障碍,且可能有害。

VICTORY为随机、双盲、安慰剂对照3期试验,在24个烧伤中心纳入238例成人深二度及以上烧伤面积≥20%且需植皮的患者,随机接受静脉维生素C(50 mg/kg每6小时共96小时)或安慰剂。主要复合终点(28天死亡率+持续器官功能障碍)维生素C组40.8% vs 安慰剂组29.7%(校正RR 1.28,95%CI 0.99-1.65,P=.06),跨过预设无效/危害界值致试验提前终止。28天死亡率维生素C组15.0% vs 安慰剂组7.6%(校正RR 1.96,95%CI 1.32-2.90,P=.001),住院死亡率23.3% vs 16.1%(校正RR 1.44,95%CI 1.03-2.00,P=.03)。90天内出院存活时间未改善(校正亚分布HR 0.85,95%CI 0.62-1.16,P=.31)。

要点

  • 严重烧伤成人(深二度及以上、烧伤面积≥20%、需植皮)中,大剂量静脉维生素C未减少28天死亡率和持续器官功能障碍复合终点(40.8% vs 29.7%,校正RR 1.28,95%CI 0.99-1.65,P=.06)。
  • 该复合终点跨过预设无效/危害界值,试验提前终止,提示大剂量静脉维生素C可能有害。
  • 28天死亡率维生素C组更高(15.0% vs 7.6%,校正RR 1.96,95%CI 1.32-2.90,P=.001)。
  • 住院死亡率维生素C组亦更高(23.3% vs 16.1%,校正RR 1.44,95%CI 1.03-2.00,P=.03)。
  • 90天内出院存活时间未改善(校正亚分布HR 0.85,95%CI 0.62-1.16,P=.31)。

适用人群与场景

  • 成人(≥18岁)深二度及以上烧伤覆盖≥20%体表面积且需要植皮的患者。
  • 纳入时间为2020年8月18日至2025年9月12日,来自北美、中美、南美、欧洲和亚洲的24个烧伤中心。

处置流程与药物剂量

  • 维生素C组:静脉维生素C 50 mg/kg每6小时,共96小时。
  • 对照组:匹配安慰剂。

研究设计与关键结果

  • 随机、双盲、安慰剂对照3期试验,24个烧伤中心,纳入238例患者(平均年龄48.9岁[SD 19.1],79%男性,平均烧伤面积37.0%[SD 14.6%]),维生素C组120例,安慰剂组118例。
  • 主要复合终点(28天死亡率+持续器官功能障碍,定义为第28天依赖机械通气、肾脏替代治疗或血管活性药物/正性肌力药物支持)维生素C组49例(40.8%)vs 安慰剂组35例(29.7%),校正RR 1.28(95%CI 0.99-1.65),P=.06,跨过预设无效/危害界值,试验提前终止。
  • 90天内出院存活时间未改善:校正亚分布HR 0.85(95%CI 0.62-1.16),P=.31。
  • 28天死亡率维生素C组15.0% vs 安慰剂组7.6%,校正RR 1.96(95%CI 1.32-2.90),P=.001。
  • 住院死亡率维生素C组23.3% vs 安慰剂组16.1%,校正RR 1.44(95%CI 1.03-2.00),P=.03。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照3期临床试验。
  • 试验因无效/危害提前终止。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 在严重烧伤成人中,大剂量静脉维生素C未减少28天死亡率和持续器官功能障碍,且可能有害;作者结论认为该治疗可能有害。

指南或共识出处

  • ClinicalTrials.gov注册号:NCT04138394

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Severe burn injury triggers systemic inflammation that can lead to multiple organ dysfunctions and death. High-dose intravenous vitamin C has been proposed to mitigate these effects, but strong evidence in patients with burn injury is lacking.

OBJECTIVE: To evaluate the efficacy of high-dose intravenous vitamin C in patients with severe burn injury.

DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled phase 3 trial conducted across 24 burn centers in North, Central, and South America; Europe; and Asia. Adults (≥18 years) with deep second- and/or third-degree burns covering 20% or more of total body surface area and requiring skin grafting were enrolled between August 18, 2020, and September 12, 2025. Final follow-up was completed in March 2026. The trial was stopped early after the first prespecified interim analysis for futility/harm.

INTERVENTIONS: Patients were randomly assigned (1:1) to receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours) or matched placebo.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of 28-day mortality and persistent organ dysfunction (defined as dependence on mechanical ventilation, kidney replacement therapy, or vasopressor/inotrope support at day 28). The main secondary outcome was time to discharge alive from hospital within 90 days.

RESULTS: Among 238 patients enrolled (mean age, 48.9 [SD, 19.1] years; 79% male; mean total body surface area, 37.0% [SD, 14.6%]), 120 were assigned to vitamin C and 118 to placebo. The primary composite outcome occurred in 49 patients (40.8%) in the vitamin C group and 35 patients (29.7%) in the placebo group (adjusted risk ratio [RR], 1.28 [95% CI, 0.99-1.65]; P = .06), crossing the prespecified futility/harm threshold and prompting early trial termination. Time to discharge alive from hospital within 90 days was not improved (adjusted subdistribution hazard ratio, 0.85 [95% CI, 0.62-1.16]; P = .31). Twenty-eight-day mortality was higher in the vitamin C group (15.0% vs 7.6%; adjusted RR, 1.96 [95% CI, 1.32-2.90]; P = .001), as was hospital mortality (23.3% vs 16.1%; adjusted RR, 1.44 [95% CI, 1.03-2.00]; P = .03).

CONCLUSIONS AND RELEVANCE: Among patients with severe burn injury, high-dose intravenous vitamin C did not reduce 28-day mortality and persistent organ dysfunction and is possibly harmful.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04138394.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Stoppe C, Hill A, Cancio LC, et al. High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury: The VICTORY Randomized Clinical Trial. JAMA. 2026. PMID: 42267875. doi:10.1001/jama.2026.10616

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。